$0.691
+0.012 (+1.68%)收盤時
- High
- 0.706
- Open
- 0.680
- VWAP
- 0.69
- Vol
- 147.17K
- Mkt Cap
- —
- Low
- 0.680
- Amount
- 101.91K
- EV/EBITDA, TTM
- 0.00
Rocket One Inc. is an artificial intelligence (AI) semiconductor infrastructure company. The Company is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic artificial intelligence (AI) chip technology designed for radiation-tolerant, energy-constrained environments such as low-earth orbit, deep-space platforms, and defense systems. It operates through two segments, which include Biopharmaceutical and AI semiconductor infrastructure. It is also focused on a nanomagnetic matrix multiplier, Skyrmion Spintronic memory, and Swarm Stage AI. The Company's biotechnology pipeline includes HT-001, HT-KIT, HT-ALZ, and its glial cell line derived neurotrophic factor (GDNF)-based metabolic program. The HT-001 is used to treat epidermal growth factor receptor (EGFR)-induced skin disorders. The HT-KIT drug is used to treat the receptor tyrosine kinase KIT in mast cells.
AI analysis of Rocket One Inc (RKTO)
sellRocket One Inc is not a good buy right now due to its extremely low RSI of 13.885, indicating oversold conditions, and a staggering year-to-date change of -47.80%.
估值指標
事件時間軸
資訊
1.008-24PRnewswireRocket One Inc. to Attend Counter Drone Summit
8.508-24NewsfilterRocket One Inc. to Attend Counter Drone Summit
7.508-18PRnewswireRocket One Launches Drone Swarm Technology for U.S. Defense
7.508-11PRnewswireRocket One Joins Seagate Partner Program to Enhance AI Infrastructure
8.507-30PRnewswireRocket One Signs Patent License Agreement with NASA to Enhance AI and Space Tech
RKTO FAQ — answered by Alphio AI
Rocket One Inc. is an artificial intelligence (AI) semiconductor infrastructure company. The Company is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic artificial intelligence (AI) chip technology designed for radiation-tolerant, energy-constrained environments such as low-earth orbit, deep-space platforms, and defense systems. It operates through two segments, which include Biopharmaceutical and AI semiconductor infrastructure. It is also focused on a nanomagnetic matrix multiplier, Skyrmion Spintronic memory, and Swarm Stage AI. The Company's biotechnology pipeline includes HT-001, HT-KIT, HT-ALZ, and its glial cell line derived neurotrophic factor (GDNF)-based metabolic program. The HT-001 is used to treat epidermal growth factor receptor (EGFR)-induced skin disorders. The HT-KIT drug is used to treat the receptor tyrosine kinase KIT in mast cells. It operates in the Healthcare sector.
Rocket One Inc is not a good buy right now due to its extremely low RSI of 13.885, indicating oversold conditions, and a staggering year-to-date change of -47.80%.
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。